Adamis Pharmaceuticals Corp (ADMP)

[66Mustang]

The US has agreed to buy 1.7M courses of the Merck stuff for $1.2B! So that's over $700 per patient! That is awesome news for Adamis!

If Merck can get $700 for a 50/50 chance of helping a patient, then a 90%+ efficacy anticipated from Tempol should be worth waaaay more per patient, and if you ask anyone if they want a 50% chance of being cured or a 95% chance of being cured, I think we will see Adamis as a clear winner.

Couple that with ADMP's philosophy of NOT price gouging their customers, as shown by their offering of the least expensive epipens available, and we can see a future in which Adamis should absolutely dominate the COVID treatment market space.